Druck Icon

Eckert & Ziegler: Re-Enter the U.S Market with Therapeutic Products

(Ad hoc press release)

Berlin, December 3rd, 2009. The Radiation Therapy Division of Eckert & Ziegler (ISIN DE0005659700) is preparing its re-entry into the U.S. market. As the Belgian portfolio company IBt Bebig reported last night, it has entered into a strategic alliance with Core Oncology Inc. of Santa Barbara, California, USA. The agreement calls for covering initially the cross marketing of products of both companies and the definition of mutual R&D programs. As part of the agreement, IBt Bebig made a two million USD investment in Core Oncology. The investment has taken the form of a subordinated loan maturing before the end of 2010. Both groups are investigating the possibilities to collaborate further together. The board of Eckert & Ziegler expects already in 2010 stimuli from the close collaboration for further growth in revenues and profits of the Therapy segment. It is also expected that the Radiation Therapy Division, like the whole group, can at least double its revenues within the next five years while maintaining the profitability.

For further details see also the publication at www.ibt-bebig.eu

The Board of Directors